The rating agency for this Bond is IND-RA, a SEBI registered rating agency.
What is rating?
Rating reflects its creditworthiness and past performance. It may change based on the company’s financial health and ability to repay.
Categories
Lowest risk
AAA
Low risk
AA+, AA, AA-
Moderate risk
A+, A, A-
High risk
BBB+, BBB, BBB-
Highest risk
BB+, BB, BB-, B, B-, C, D
YTM
10.80%
Price/unit₹75,373.14
Tenure26 months
Interest payoutQuarterly
Principal payoutQuarterly
Key terms
YTM (Yield to Maturity)Yield to Maturity is annual yield percentage of bond, assuming recurring interest and principal payout are re-invested at same rate/same bond. It is XIRR of bonds.Learn more
TenureDuration left until the bond matures and pays out interest and principal
Interest payoutInterval at which interest will be paid
Principal payoutInterval at which invested principal will be returned
Principal is returned in quarterly instalments
The Principal is returned in quarterly instalments for this Bond, so you receive a portion of your invested amount back regularly.
As principal is returned, interest is earned on the outstanding principal.
Calculate your returns
You invest₹00 qty
You get₹0
Interest +₹0
+ ₹25K
+ ₹50K
+ ₹1L
+ ₹2L
Payout Schedule
Maturing on 20 Jan '29 • Quarterly payout
Upcoming payouts
No upcoming payouts
About
Dishman Carbogen Amcis Limited (DCAL), incorporated in 1983, is an integrated contract research and manufacturing services (CRAMS) player operating in the pharmaceutical sector. The company operates through two primary business segments: CRAMS, which contributed 86% to 9MFY25 revenue, and Marketable Molecules (MM), contributing 14%. The CRAMS segment is further split into Carbogen Amcis (EU) and Dishman India, providing process research, drug development, and active pharmaceutical ingredient (API) manufacturing services. DCAL operates 10 manufacturing sites across six countries (India, UK, Switzerland, Netherlands, China, and France) approved by various global health authorities, with a core therapeutic focus on high-value areas like oncology.;
Pros and Cons
Pros
Cons
DCAL possesses a well-diversified business profile across CRAMS and marketable molecules, supported by 10 global manufacturing facilities approved by major regulatory agencies including the USFDA.
The Carbogen Amcis European business delivers stable operational performance with strong order book visibility, supported by long-standing relationships with innovator pharmaceutical companies.
Revenue visibility has improved significantly following the completion of major capital expenditure programs and the successful clearance of regulatory audits by USFDA, EDQM, AIFA, and PMDA.
The company maintains a strong strategic focus on high value-added therapeutic areas, with oncology products accounting for more than 50% of total revenues.
The liquidity position remains adequate, backed by unrestricted cash balances, current investments, and unutilized fund-based bank limits to cover upcoming debt servicing requirements.
Other details
Clean price₹74,674.51
Dirty price₹75,373.14
Current yield10.80%
Security cover--
Issue size50.00Cr
Original bond tenure36 months
TrusteeAxis Trustee Services Limited
Mode of issueNCD
Listed onNSE
Listing date20 Jan 2026
Coupon rate10.00%
Other details
Clean priceThe bond's original price without earned interest on it.
Dirty priceThe total price you pay - bond price plus accrued interest.
Security coverThe value of assets pledged by the issuer as backup, shown as a multiple of the outstanding loan amount.
Issue sizeThe total amount of money the company is raising through this bond issue.
Original bond tenureThe total duration of the bond from issue date to maturity date.
TrusteeAn independent entity appointed to protect bondholders' interests and monitor the issuer.
Mode of issueHow the bond is offered to investors (e.g., public issue open to all investors).
Listed onStock exchanges where the bond can be bought and sold after issuance.
Listing dateThe date from which the bond became available for trading on the stock exchange.
Maturity dateThe date when the company repays the bond's principal amount.
Coupon rateThe fixed annual interest rate paid to investors on the bond's face value.
Current yieldThe annual interest you earn divided by the bond's current market price.